公开(公告)号：US20170166578A1

公开(公告)日：2017-06-15

申请号：US15039607

申请日：2014-12-17

Applicant: Merck Sharp & Dohme Corp.

Inventor： William K. Hagmann ,  Bing Li ,  Jason W. Szewczyk ,  Bowei Wang ,  Dann Parker ,  Timothy Blizzard ,  Hubert Josien ,  Purakkattle Biju ,  Harry Chobanian ,  Candido Gude ,  Ravi P. Nargund ,  Barbara Pio ,  Qun Dang ,  Linus S. Lin ,  Bin Hu ,  Mingxiang Cui ,  Zhengxia Chen ,  Meibi Dai ,  Zaihong Zhang ,  Ying Lv ,  Lili Tian

IPC: C07D493/04 ,  C07D213/64 ,  A61K31/44 ,  C07D409/12 ,  A61K31/4436 ,  C07D401/04 ,  A61K31/4545 ,  C07D471/04 ,  A61K31/437 ,  C07D405/12 ,  A61K31/4433 ,  C07D401/12 ,  A61K31/4439 ,  A61K31/443 ,  C07D239/34 ,  A61K31/505 ,  C07D451/06 ,  A61K31/46 ,  C07D221/20 ,  A61K31/438 ,  A61K31/506 ,  C07D213/74 ,  C07D417/04 ,  A61K45/06

CPC classification number: C07D493/04 ,  A61K31/437 ,  A61K31/438 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06 ,  C07D213/64 ,  C07D213/74 ,  C07D221/20 ,  C07D239/34 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/04 ,  C07D451/06 ,  C07D471/04

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

公开(公告)号：US09834563B2

公开(公告)日：2017-12-05

申请号：US15039607

申请日：2014-12-17

Applicant: Merck Sharp & Dohme Corp.

Inventor： William K. Hagmann ,  Bing Li ,  Jason W. Szewczyk ,  Bowei Wang ,  Dann Parker ,  Timothy Blizzard ,  Hubert Josien ,  Purakkattle Biju ,  Harry Chobanian ,  Candido Gude ,  Ravi P. Nargund ,  Barbara Pio ,  Qun Dang ,  Linus S. Lin ,  Bin Hu ,  Mingxiang Cui ,  Zhengxia Chen ,  Meibi Dai ,  Zaihong Zhang ,  Ying Lv ,  Lili Tian

IPC: A61K31/506 ,  C07D493/04 ,  A61K45/06 ,  C07D213/64 ,  A61K31/44 ,  C07D409/12 ,  A61K31/4436 ,  C07D401/04 ,  A61K31/4545 ,  C07D471/04 ,  A61K31/437 ,  C07D405/12 ,  A61K31/4433 ,  C07D401/12 ,  A61K31/4439 ,  A61K31/443 ,  C07D239/34 ,  A61K31/505 ,  C07D451/06 ,  A61K31/46 ,  C07D221/20 ,  A61K31/438 ,  C07D213/74 ,  C07D417/04

CPC classification number: C07D493/04 ,  A61K31/437 ,  A61K31/438 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/46 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06 ,  C07D213/64 ,  C07D213/74 ,  C07D221/20 ,  C07D239/34 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/04 ,  C07D451/06 ,  C07D471/04

Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.